Biotech Licensing and M&A Predictions for 2023
Biotech industry poised for boom: 2023 licensing & M&A predictions.
Menu
Write Right Now
Why don't companies write business plans anymore? Are they useless? Is it simply faster to put together 10 slides? In this post, we discuss this interesting question.
Will Coronavirus Affect Business Development?
Will the current coronavirus situation affect biotech and pharma business development?Yes...and No. As with most things, the answer depends on your point of view, the market you happen to be in,…
Can AI Revolutionize Business Development?
Want to spend an entire decade surfing the web? Try finding and reading every article on “artificial intelligence.” A serious branch of computer science has rapidly turned into a buzzword…
Good Article: Strategic Alliances Between Int’l Stakeholders
The August Edition of Life Science Leader has a summary of a panel discussion. The article is available here, and is well worth the time to read it if you…
Comments on Biotech Showcase Webinar
This morning, our friends at EBD and MacDougall Biomedical Communications presented a very good webinar on preparing for the upcoming festivities in San Francisco. In case you missed it, I…
License-Ability Analysis Helps Focus BD Efforts
We go to a lot of conferences. And, as a result, we see a lot of assets being marketed by pharma & biotech executives which will likely never find a…
Drug Delivery is Alive and Well
The announcement of the Allergan acquisition of MAP Pharmaceuticals for nearly $1 billion (and the NuPathe approval) is a good reminder of the potential value (both clinical and financial) of reformulation and drug…
Observations from JPM 2013
Lacerta Bio, along with approximately 10,000 other life science investors, executives, consultants, service providers, hangers-on, and many others, congregated in San Francisco for a variety of conferences, including the JP…
Predictions for 2013
Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we've discussed internally as we look forward to 2013:…